Ward Capoen

After several years of dismal market activity, 2024 is already looking up for deals in the pharmaceutical industry, with a recent flurry of billion-dollar mergers and acquisitions. Is this trend being driven by the impending loss of revenue caused by soon-to-expire blockbuster drug patents? And what does it mean for earlier-stage biotech startups?
Bankruptcy, closures, and layoffs – oh my! But it’s not all doom and gloom for the biotech boom. Innovation is still in demand, and although the VC landscape is changing, companies are still able to find funds.
The stock market value of biotech companies has been crashing lately, bitterly reminiscent of the dot-com bubble burst in the early 2000s. Should investors and startups be panicking? Or might there be a silver lining to this stormy cloud?